↓ Skip to main content

Cancer Vaccines

Overview of attention for book
Attention for Chapter 429: Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Chapter number 429
Book title
Cancer Vaccines
Published in
Current topics in microbiology and immunology, February 2015
DOI 10.1007/82_2015_429
Pubmed ID
Book ISBNs
978-3-31-923909-5, 978-3-31-923910-1
Authors

Bruce Acres, Gisele Lacoste, Jean-Marc Limacher, Acres, Bruce, Lacoste, Gisele, Limacher, Jean-Marc

Abstract

Several approaches to antigen-specific immunotherapy of cancer antigen-specific immunotherapy of cancerantigen-specific immunotherapy of cancer have been tested clinically. In this chapter, we will describe studies done with the antigen MUC1. Tested MUC1 therapeutic vaccinesMUC1 therapeutic vaccines include the following: monoclonal antibodies (MAbs) specific for MUC1; synthetic and recombinant polypeptides from the protein sequence of MUC1; dendritic cells carrying MUC1; RNA and DNA vaccinations; and recombinant viruses carrying the MUC1 DNA sequence. Chemotherapy of cancer aims to be toxic to the cancer cells with manageable side effects to the patient. In contrast, antigen-specific immunotherapy of cancer aims to treat the patient, such that the patient is then able to control and eventually eliminate their cancer cells. It is therefore important to know the immune statusimmune status of each cancer patientcancer patient prior to therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 25%
Student > Postgraduate 2 17%
Researcher 2 17%
Professor 1 8%
Student > Bachelor 1 8%
Other 0 0%
Unknown 3 25%
Readers by discipline Count As %
Agricultural and Biological Sciences 3 25%
Chemistry 2 17%
Nursing and Health Professions 1 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Medicine and Dentistry 1 8%
Other 1 8%
Unknown 3 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2019.
All research outputs
#14,657,483
of 23,923,788 outputs
Outputs from Current topics in microbiology and immunology
#386
of 690 outputs
Outputs of similar age
#132,145
of 257,719 outputs
Outputs of similar age from Current topics in microbiology and immunology
#3
of 4 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 690 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,719 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.